Purple pigments: The pathophysiology of acute porphyric neuropathy

Clinical Neurophysiology

Volumn 122, Issue 12, 2011, Pages 2336-2344

  Lin, Cindy S Y ^a   Lee, Ming Jen ^b   Park, Susanna B ^c   Kiernan, Matthew C ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Acute intermittent porphyria; Haem; Peripheral neuropathy; Porphyric neuropathy

Indexed keywords

HEME; HEME ARGINATE; HEMIN; PORPHYRIN;

ABDOMINAL PAIN; ACUTE INTERMITTENT PORPHYRIA; ANXIETY; AUTONOMIC NEUROPATHY; COMA; CONSTIPATION; CONVULSION; DEPRESSION; ELECTRODIAGNOSIS; HEME SYNTHESIS; HUMAN; HYPERTENSION; HYPONATREMIA; NAUSEA AND VOMITING; NERVE FIBER DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; NUCLEOTIDE SEQUENCE; PAIN; PALLIATIVE THERAPY; PARESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SEIZURE; TACHYCARDIA; WEAKNESS;

ANIMALS; HEME; HUMANS; HYDROXYMETHYLBILANE SYNTHASE; MICE; MUTATION; PERIPHERAL NERVOUS SYSTEM DISEASES; PIGMENTS, BIOLOGICAL; PORPHYRIA, ACUTE INTERMITTENT;

EID: 80855147492     PISSN: 13882457     EISSN: 18728952     Source Type: Journal    
DOI: 10.1016/j.clinph.2011.07.036     Document Type: Review

References (129)

1. Aarsand A.K., Petersen P.H., Sandberg S. Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria. Clin Chem 2006, 52:650-656.
2. Albers J.W., Fink J.K. Porphyric neuropathy. Muscle Nerve 2004, 30:410-422.
3. Albers J.W., Robertson W.C.J., Daube J.R. Electrodiagnostic findings in acute porphyric neuropathy. Muscle Nerve 1978, 1:292-296.
4. American Porphyria Foundation (2010). Drug Safety in Acute Porphyria. Available from: , [accessed 1 April 2011]. http://www.porphyriafoundation.com/testing-and-treatment/drug-safety-in-acute-porphyria.
5. Anderson K.E., Alvares A.P., Sassa S., Kappas A. Studies in porphyria. V. Drug oxidation rates in hereditary hepatic porphyria. Clin Pharmacol Ther 1976, 19:47-54.
6. Anderson K., Sassa S., Bishop D., Desnick R. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. Metabolic and molecular bases of inherited disease 2001, 2991-3062. McGraw-Hill, New York. C. Scriver, A. Beaudet, W. Sly, D. Valle, B. Childs, K. Kinzler (Eds.).
7. Anderson K.E., Bloomer J.R., Bonkovsky H.L., Kushner J.P., Pierach C.A., Pimstone N.R., et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005, 142:439-450.
8. Andersson C., Floderus Y., Wikberg A., Lithner F. The W198X and R173W mutations in the porphobilinogen deaminase gene in acute intermittent porphyria have higher clinical penetrance than R167W. A population based study. Scand J Clin Lab Invest 2000, 60:643-648.
9. Arnold W.N. The illness of Vincent van Gogh. J Hist Neurosci 2004, 13:22-43.
10. Badminton M.N., Elder G.H. Management of acute and cutaneous porphyrias. Int J Clin Pract 2002, 56:272-278.
11. Barohn R.J., Sanchez J.A., Anderson K.E. Acute peripheral neuropathy due to hereditary coproporphyria. Muscle Nerve 1994, 17:793-799.
12. Baumstark F. Zwei pathologische harnfarbstoff. Pflugers Arch Ges Physiol 1874, 9:568-584.
13. Becker D., Viljoen D., Kramer S. The inhibition of red cell and brain atpase by [delta]-aminolaevulinic acid. Biochim Biophys Acta 1971, 225:26-34.
14. Becker D.M., Goldstuck N., Kramer S. Effect of delta-aminolaevulinic acid on the resting membrane potential of frog sartorius muscle. S Afr Med J 1975, 49:1790-1792.
15. Bergdahl I.A., Grubb A., Schutz A., Desnick R.J., Wetmur J.G., Sassa S., et al. Lead binding to delta-aminolevulinic acid dehydratase (ALAD) in human erythrocytes. Pharmacol Toxicol 1997, 81:153-158.
16. Bonkovsky H.L., Tshudy D.P., Collins A., Doherty J., Bossenmaier I., Cardinal R., et al. Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by intravenous infusions of hematin. Proc Natl Acad Sci USA 1971, 68:2725-2729.
17. Burke D., Kiernan M.C., Bostock H. Excitability of human axons. Clin Neurophysiol 2001, 112:1575-1585.
18. Bylesjö I., Forsgren L., Lithner F., Boman K. Epidemiology and clinical characteristics of seizures in patients with acute intermittent porphyria. Epilepsia 1996, 37:230-235.
19. Bylesjö I., Wikberg A., Andersson C. Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study. Scand J Clin Lab Invest 2009, 69:612-618.
20. Cavanagh J.B., Mellick R.S. On the nature of the peripheral nerve lesions associated with acute intermittent porphyria. J Neurol Neurosurg Psychiatry 1965, 28:320-327.
21. Chernova T., Nicotera P., Smith A.G. Heme deficiency is associated with senescence and causes suppression of N-methyl-d-aspartate receptor subunits expression in primary cortical neurons. Mol Pharmacol 2006, 69:697-705.
22. Chretien S., Dubart A., Beaupain D., Raich N.G., Grandchamp B., Rosa J., Goossens M., et al. Alternative transcription and splicing of the human porphobilinogen deaminase gene result either in tissue-specific or in housekeeping expression. Proc Natl Acad Sci USA 1988, 85:6-10.
23. Crimlisk H.L. The little imitator - porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psychiatry 1997, 62:319-328.
24. De Siervi A., Rossetti M.V., Parera V.E., Mendez M., Varela L.S., del C Batlle A.M. Acute intermittent porphyria: biochemical and clinical analysis in the argentinean population. Clin Chim Acta 1999, 288:63-71.
25. Defanti C.A., Sghirlanzoni A., Bottacchi E., Peluchetti D. Poprhyric neuropathy: a clinical, neurophysiological and morphological study. Ital J Neurol Sci 1985, 6:521-526.
26. Demasi M., Penatti C.A.A., Delucia R., Bechara E.J.H. The prooxidant effect of 5-aminolevulinic acid in the brain tissue of rats: implications in neuropsychiatric manifestations in porphyrias. Free Radic Biol Med 1996, 20:291-299.
27. Dhand U.K. Clinical approach to the weak patient in the intensive care unit. Res Care 2006, 51:1024-1040.
28. Diot E., Corcia P., Zannad N., Chauvet M.A., Borie M.J., Maillot F. Favorable outcome of acute porphyric neuropathy after treatment with heme arginate. Rev Neurol 2007, 163:1100-1102.
29. Doss M., Benkmann H.G., Goedde H.W. Delta-aminolevulinic acid dehydrase (porphobilinogen synthase) in two families with inherited enzyme deficiency. Clin Genet 1986, 30:191-198.
30. Dowdle E., Mustard P., Spong N., Eales L. The metabolism of (5-14c)delta-aminolaevulic acid in normal and porphyric human subjects. Clin Sci 1968, 34:233-251.
31. Duchen M.R. Effects of metabolic inhibition on the membrane properties of isolated mouse primary sensory neurones. J Physiol 1990, 424:387-409.
32. Egger N.G., Lee C., Anderson K. Disorders of heme biosynthesis. Inborn metabolic diseases: diagnosis and treatment 2006, Springer, Heidelberg. J. Fernandes, J.-M. Saudubray, G. Vanden Berghe, J.H. Walter (Eds.).
33. Elder G.H., Hift R.J., Meissner P.N. The acute porphyrias. Lancet 1997, 349:1613-1617.
34. Ferrer M.D., Sureda A., Tauler P., Palacín C., Tur J.A., Pons A. Impaired lymphocyte mitochondrial antioxidant defences in variegate porphyria are accompanied by more inducible reactive oxygen species production and DNA damage. Br J Haematol 2010, 149:759-767.
35. Floderus Y., Shoolingin-Jordan P., Harper P. Acute intermittent porphyria in Sweden. Molecular, functional and clinical consequences of some new mutations found in the porphobilinogen deaminase gene. Clin Genet 2002, 62:288-297.
36. Flügel K.A., Druschky K.F. Electromyogram and nerve conduction in patients with acute intermittent porphyria. J Neurol 1977, 214:267-279.
37. Foran S.E., Ábel G. Guide to porphyrias: a historical and clinical perspective. Am J Clin Pathol 2003, 119(Suppl. 1):S86-S93.
38. Gibson J.B., Goldberg A. The neuropathology of acute porphyria. J Pathol Bacteriol 1956, 71:495-509.
39. Goldberg A. Acute intermittent porphyria: a study of 50 cases. Q J Med 1959, 28:183-209.
40. Gorchein A., Webber R. Delta-aminolaevulinic acid in plasma, cerebrospinal fluid, saliva and erythrocytes: Studies in normal, uraemic and porphyric subjects. Clin Sci 1987, 72:103-112.
41. Gordon P.H., Wilbourn A.J. Early electrodiagnostic findings in Guillain-Barré syndrome. Arch Neurol 2001, 58:913-917.
42. Grandchamp B., De Verneuil H., Beaumont C., Chretien S., Walter O., Nordmann Y. Tissue-specific expression of porphobilinogen deaminase. Two isoenzymes from a single gene. Eur J Biochem 1987, 162:105-110.
43. Grandchamp B., Picat C., Mignotte V., Wilson J.H., Te Velde K., Sandkuyl L., et al. Tissue-specific splicing mutation in acute intermittent porphyria. Proc Natl Acad Sci USA 1989, 86:661-664.
44. Günther H. Die Hämatoporphyrie. Dtsch Arch Klin Med 1911, 105:89-146.
45. Gürses C., Durukan A., Sencer S., Akça S., Baykan B., Gökyiĝit A. A severe neurological sequela in acute intermittent porphyria: presentation of a case from encephalopathy to quadriparesis. Br J Radiol 2008, 81:e135-e140.
46. Hadden R.D., Hughes R.A. Management of inflammatory neuropathies. J Neurol Neurosurg Psychiatry 2003, 74(Suppl. 2):ii9-ii14.
47. Hadden R.D., Cornblath D.R., Hughes R.A., Zielasek J., Hartung H.P., Toyka K.V., Swan A.V. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 1998, 44:780-788.
48. Helson L., Braverman S., Mangiardi J. Delta-aminolevulinic acid effects on neuronal and glial tumor cell lines. Neurochem Res 1993, 18:1255-1258.
49. Herrick A.L., McColl K.E. Acute intermittent porphyria. Best Pract Res Clin Gastroenterol 2005, 19:235-249.
50. Herrick A.L., McColl K.E., Moore M.R., Cook A., Goldberg A. Controlled trial of haem arginate in acute hepatic porphyria. Lancet 1989, 1:1295-1297.
51. Hierons R. Changes in the nervous system in acute porphyria. Brain 1957, 80:176-192.
52. Hift R.J., Meissner P.N. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine 2005, 84:48-60.
53. Hiraga A., Kuwabara S., Ogawara K., Misawa S., Kanesaka T., Koga M., Yuki N., Hattori T., Mori M. Patterns and serial changes in electrodiagnostic abnormalities of axonal Guillain-Barré syndrome. Neurology 2005, 64:856-860.
54. Hoppe-Seyler F. Uber hematoporphyrin. Tubinger Medizinisch-Chemische Untersuchungen 1871, 4:531-539.
55. Hrdinka M., Puy H., Martasek P. May 2006 update in porphobilinogen deaminase gene polymorphisms and mutations causing acute intermittent porphyria. Comparison with the situation in Slavic population. Physiol Res 2006, 55(Suppl. 2):S119-S136.
56. Hughes R.A.C., Cornblath D.R. Guillain-Barré syndrome. Lancet 2005, 366:1653-1666.
57. Johansson A., Nowak G., Moller C., Blomberg P., Harper P. Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria. Mol Ther 2004, 10:337-343.
58. Kaji R., Sumner A.J. Ouabain reverses conduction disturbances in single demyelinated nerve fibres. Neurology 1989, 39:1364-1368.
59. Kauppinen R. Porphyrias. Lancet 2005, 365:241-252.
60. Kauppinen R., Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine 1992, 71:1-13.
61. Kauppinen R., von und zu Fraunberg M. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Clin Chem 2002, 48:1891-1900.
62. Kiernan M.C., Bostock H. Effects of membrane polarization and ischaemia on the excitability properties of human motor axons. Brain 2000, 123:2542-2551.
63. Kiernan M.C., Burke D., Andersen K.V., Bostock H. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve 2000, 23:399-409.
64. Kiernan M.C., Lin C.S.Y., Andersen K.V., Murray N.M.F., Bostock H. Clinical evaluation of excitability measures in sensory nerve. Muscle Nerve 2001, 24:883-892.
65. Kochar D.K., Poonia A., Kumawat B.L., Shubhakaran Gupta.B.K. Study of motor and sensory nerve conduction velocities, late responses (F-wave and H-reflex) and somatosensory evoked potential in latent phase of intermittent acute porphyria. Electromyogr Clin Neurophysiol 2000, 40:73-79.
66. Kokubun N., Nishibayashi M., Uncini A., Odaka M., Hirata K., Yuki N. Conduction block in acute motor axonal neuropathy. Brain 2010, 133:2897-2908.
67. Krishnan A.V., Lin C.S.Y., Park S.B., Kiernan M.C. Axonal ion channels from bench to bedside: a translational neuroscience perspective. Prog Neurobiol 2009, 89:288-313.
68. Kuo H.-C., Lee M.-J., Chuang W.-L., Huang C.-C. Acute intermittent porphyria with peripheral neuropathy: a follow-up study after hematin treatment. J Neurol Sci 2007, 260:231-235.
69. Laiwah A.C., Macphee G.J., Boyle P., Moore M.R., Goldberg A. Autonomic neuropathy in acute intermittent porphyria. J Neurol Neurosurg Psychiatry 1985, 48:1025-1030.
70. Lavandera J., Batlle A., Buzaleh A. Metabolization of porphyrinogenic agents in brain: involvement of the phase i drug metabolizing system. A comparative study in liver and kidney. Cell Mol Neurobiol 2007, 27:717-729.
71. Lee G.Y., Astrin K.H., Desnick R.J. Acute intermittent porphyria: a single-base deletion and a nonsense mutation in the human hydroxymethylbilane synthase gene, predicting truncations of the enzyme polypeptide. Am J Med Genet 1995, 58:155-158.
72. Lin C.S.Y., Krishnan A.V., Lee M.-J., Zagami A.S., You H.-L., Yang C.-C., et al. Nerve function and dysfunction in acute intermittent porphyria. Brain 2008, 131:2510-2519.
73. Lindberg R.L., Porcher C., Grandchamp B., Ledermann B., Burki K., Brandner S., et al. Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria. Nat Genet 1996, 12:195-199.
74. Lindberg R.L.P., Martini R., Baumgartner M., Erne B., Borg J., Zielasek J., et al. Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. J Clin Invest 1999, 103:1127-1134.
75. Ludwig G.D., Goldberg M. Hyponatremia in acute intermittent porphyria probably resulting from inappropriate secretion of antidiuretic hormone. Ann NY Acad Sci 1963, 104:710-734.
76. Macalpine I., Hunter R. The " Insanity" Of King George 3d: a classic case of porphyria. Br Med J 1966, 1:65-71.
77. Macalpine I., Hunter R., Rimington C. Porphyria in the royal houses of Stuart, Hanover, and Prussia. A follow-up study of George 3d's illness. Br Med J 1968, 1:7-18.
78. Maramattom B.V., Zaldivar R.A., Glynn S.M., Eggers S.D., Wijdicks E.F. Acute intermittent porphyria presenting as a diffuse encephalopathy. Ann Neurol 2005, 57:581-584.
79. Maytham D.V., Eales L. Electrodiagnostic findings in porphyria. S Afr Med J 1971, 25:99-100.
80. Meisler M., Wanner L., Eddy R.E., Shows T.B. The UPS locus encoding uroporphyrinogen I synthase is located on human chromosome 11. Biochem Biophys Res Commun 1980, 95:170-176.
81. Mercelis R., Hassoun A., Verstraeten L., De Bock R., Martin J.J. Porphyria neuropathy and hereditary delta-aminolevulinic acid dehydratase deficiency in an adult. J Neurol Sci 1990, 95:39-47.
82. Meyer U.A., Strand L.J., Doss M., Rees A.C., Marver H.S. Intermittent acute porphyria - demonstration of a genetic defect in porphobilinogen metabolism. N Engl J Med 1972, 286:1277-1282.
83. Meyer U.A., Schuurmans M.M., Lindberg R.L. Acute porphyrias: pathogenesis of neurological manifestations. Semin Liver Dis 1998, 18:43-52.
84. Meyer R.P., Lindberg R.L.P., Hoffmann F., Meyer U.A. Cytosolic persistence of mouse brain CYP1A1 in chronic heme deficiency. Biol Chem 2005, 386:1157-1164.
85. Mgone C.S., Lanyon W.G., Moore M.R., Louie G.V., Connor J.M. Detection of a high mutation frequency in exon 12 of the porphobilinogen deaminase gene in patients with acute intermittent porphyria. Hum Genet 1993, 92:619-622.
86. Millward L., Kelly P., King A., Peters T. Anxiety and depression in the acute porphyrias. J Inherit Metab Dis 2005, 28:1099-1107.
87. Monteiro H.P., Bechara E.J.H., Abdalla D.S.P. Free radicals involvement in neurological porphyrias and lead poisoning. Mol Cell Biochem 1991, 103:73-83.
88. Moore M.R. The pathogenesis of acute porphyria. Mol Aspects Med 1990, 11:49-57.
89. Morita K., David G., Barrett J.N., Barrett E.F. Posttetanic hyperpolarization produced by electrogenic Na+-K+ pump in lizard axons impaled near their motor terminals. J Neurophysiol 1993, 70:1874-1884.
90. Mustajoki P. Normal erythrocyte uroporphyrinogen I synthase in a kindred with acute intermittent porphyria. Ann Intern Med 1981, 95:162-166.
91. Mustajoki P., Nordmann Y. Early administration of heme arginate for acute porphyric attacks. Arch Intern Med 1993, 153:2004-2008.
92. Mustajoki P., Seppâlâinen A.M. Neuropathy in latent hereditary hepatic porphyria. Br Med J 1975, 2:310-312.
93. Mustajoki P., Kauppinen R., Lannfelt L., Lilius L., Koistinen J. Frequency of low erthyrocyte porphobilinogen deaminase activity in Finland. J Intern Med 1992, 231:389-395.
94. Mustajoki P., Timonen K., Gorchein A., Seppâlâinen A.M., Matikainen E., Tenhunen R. Sustained high plasma 5-aminolaevulinic acid concentration in a volunteer: no porphyric symptoms. Eur J Clin Invest 1992, 22:407-411.
95. Muthane U.B., Vengamma B., Bharathi K.C., Mamatha P. Porphyric neuropathy: prevention of progression using haeme-arginate. J Intern Med 1993, 234:611-613.
96. Nordmann Y., Puy H. Human hereditary hepatic porphyrias. Clin Chim Acta 2002, 325:17-37.
97. Onuki J., Chen Y., Teixeira P.C., Schumacher R.I., Medeiros M.H.G., Van Houten B., et al. Mitochondrial and nuclear DNA damage induced by 5-aminolevulinic acid. Arch Biochem Biophys 2004, 432:178-187.
98. Puy H., Deybach J.-C., Lamoril J., Robreau A.M., Da Silva V., Gouya L., et al. Molecular epidemiology and diagnosis of pbg deaminase gene defects in acute intermittent porphyria. Am J Hum Genet 1997, 60:1373-1383.
99. Puy H., Gouya L., Deybach J.-C. Porphyrias. Lancet 2010, 375:924-937.
100. Reuben A. Seeing purple. Hepatology 2006, 43:1403-1409.
101. Ridley A. The neuropathy of acute intermittent porphyria. Q J Med 1969, 38:307-333.
102. Rimington C. Types of porphyria: some thoughts about biochemical mechanisms involved. Ann NY Acad Sci 1963, 104:666-675.
103. Russell V.A., Lamm M.C., Taljaard J.J. Inhibition of Na+, K+-ATPase activity by delta-aminolevulinic acid. Neurochem Res 1983, 8:1407-1415.
104. Sassa S. Modern diagnosis and management of the porphyrias. Br J Haematol 2006, 135:281-292.
105. Sengupta A., Hon T., Zhang L. Heme deficiency suppresses the expression of key neuronal genes and causes neuronal cell death. Mol Brain Res 2005, 137:23-30.
106. Simon N., Herkes G. The neurologic manifestations of the acute porphyrias. J Clin Neurosci 2011.
107. Solinas C., Vajda F.J. Neurological complications of porphyria. J Clin Neurosci 2008, 15:263-268.
108. Stewart J.D. Peripheral nerve fascicles: Anatomy and clinical relevance. Muscle Nerve 2003, 28:525-541.
109. Stewart P.M., Hensley W.J. An acute attack of variegate porphyria complicated by severe autonomic neuropathy. Aust NZ J Med 1981, 11:82-83.
110. Sweeney V.P., Pathak M.A., Ashbury A.K. Acute intermittent porphyria: increased ALA-synthetase activity during an acute attack. Brain 1970, 93:369-380.
111. Thunell S. Porphyrins, porphyrin metabolism and porphyrias. I. Update. Scand J Clin Lab Invest 2000, 60:509-540.
112. Thunell S. Hydroxymethylbilane synthase (HMBS) deficiency. Gene reviews 2010, University of Washington, Seattle. R.A. Pagon, T.C. Bird, C.R. Dolan, K. Stephens (Eds.).
113. Thunell S., Harper P., Brock A., Petersen N.E. Porphyrins, porphyrin metabolism and porphyrias. II. Diagnosis and monitoring in the acute porphyrias. Scand J Clin Lab Invest 2000, 60:541-560.
114. Thunell S., Pomp E., Brun A. Guide to drug porphyrinogenicity prediction and drug prescription in the acute porphyrias. Br J Pharmacol 2007, 64:668-679.
115. Unzu C., Sampedro A., Mauleon I., Alegre M., Beattie S.G., de Salamanca R.E., et al. Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice. Mol Ther 2010, 19:243-250.
116. Unzu C., Sampedro A., Mauleón I., Vanrell L., Dubrot J., de Salamanca R.E., et al. Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria. J Hepatol 2010, 52:417-424.
117. Utz N., Kinkel B., Hedde J.P., Bewermeyer H. MR imaging of acute intermittent porphyria mimicking reversible posterior leukoencephalopathy syndrome. Neuroradiology 2001, 43:1059-1062.
118. Ventura P., Cappellini M., Rocchi E. The acute porphyrias: a diagnostic and therapeutic challenge in internal and emergency medicine. Intern Emerg Med 2009, 4:297-308.
119. von und zu Fraunberg M., Pischik E., Udd L., Kauppinen R. Clinical and biochemical characteristics and genotype-phenotype correlation in 143 Finnish and Russian patients with acute intermittent porphyria. Medicine 2005, 84:35-47.
120. Waldenstrom J. Studien uber porphyrie. Academic dissertation. Acta Med Scand Suppl 1937; 82.
121. Wang A.-L., Arredondo-Vega F.X., Giampietro P.F., Smith M., Anderson W.F., Desnick R.J. Regional gene assignment of human prophobilinogen deaminase and esterase A4 to chromosome 11q23-11qter. Proc Natl Acad Sci USA 1981, 78:5734-5738.
122. Watson C.J. Pursuit of the purple. JAMA 1966, 197:126-132.
123. Watson C.J., Lowry P.T., Schmid R., Hawkinson V.E., Schwartz S. The manifestations of the different forms of porphyria in relation to chemical findings. Trans Assoc Am Physicians 1951, 64:345-352.
124. Whatley S.D., Mason N.G., Woolf J.R., Newcombe R.G., Elder G.H., Badminton M.N. Diagnostic strategies for autosomal dominant acute porphyrias: retrospective analysis of 467 unrelated patients referred for mutational analysis of the HMBS, CPOX, or PPOX gene. Clin Chem 2009, 55:1406-1414.
125. With T.K. A short history of porphyrins and the porphyrias. Int J Biochem 1980, 11:189-200.
126. Yamada M., Kondo M., Tanaka M., Okeda R., Hatakeyama S., Fukui T., Tsukagoshi H. An autopsy case of actue porphyria with a decrease of both uroporphyrinogen I synthase and ferrochelatase activities. Acta Neuropathol 1984, 64:6-11.
127. Yang C.C., Kuo H.C., You H.L., Wang J., Huang C.C., Liu C.Y., et al. HMBS mutations in Chinese patients with acute intermittent porphyria. Ann Hum Genet 2008, 72:683-686.
128. Yasuda M., Bishop D.F., Fowkes M., Cheng S.H., Gan L., Desnick R.J. AAV8-mediated gene therapy prevents induced biochemical attacks of acute intermittent porphyria and improves neuromotor function. Mol Ther 2010, 18:17-22.
129. Zhang K., Peng B.-W., Sanchez R.M. Decreased IH in hippocampal area CA1 pyramidal neurons after perinatal seizure-inducing hypoxia. Epilepsia 2006, 47:1023-1028.